Carasent AB

Equities

Real-time Estimate Cboe Europe Other stock markets 08:53:00 2026-03-11 am EDT			5-day change	1st Jan Change
23.55 ^SEK	-2.69%		-1.26%	-14.03%

Mar. 09	Affärsvärlden issues buy recommendation for Carasent	FW
Mar. 05	Origo Quest Falls 6.3 Percent in February – Increases Holdings in Chemometec and Dynavox	FW

Published on 02/12/2026 at 09:30 am EST - Modified on 02/18/2026 at 12:50 pm EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to Carasent Q4 Report for 2025. [Operator Instructions]

Now I will hand the conference over to CEO, Daniel Ohman,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Mar. 09	Affärsvärlden issues buy recommendation for Carasent	FW
Mar. 05	Origo Quest Falls 6.3 Percent in February – Increases Holdings in Chemometec and Dynavox	FW
Feb. 26	Aktiespararna Adds Nelly and Bonesupport to Its Short-Term Portfolio	FW
Feb. 19	Lannebo Health and New Technology Down 5.1 Percent in January — Bico and Raysearch Weigh on Performance	FW
Feb. 19	Carasent Board Member Henric Carlsson Purchases Shares Worth Over SEK 0.2 Million	FW
Feb. 12	Carasent AB, Q4 2025 Earnings Call, Feb 12, 2026
Feb. 12	Carasent Increases Revenue and Operating Profit	FW
Feb. 11	Carasent AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 10	Origo Quest Down 2.9 Percent in January — Decline Partially Offset by Short Portfolio	FW
Feb. 06	Carol Wildhagen Declines Re-Election to the Board of Carasent	FW
Feb. 06	Kavaljer Quality Focus Down 6.1 Percent in January – Invests in CAG Group and Idun Industrier	FW
Jan. 09	Kavaljer Quality Focus Up 3.2 Percent in December – Highlights Potential in Securitas and Carasent	FW
Jan. 07	Origo Quest Rose 0.5 Percent in December – Both Long and Short Portfolios Boosted Returns in 2025	FW
Dec. 16	Carasent's own shareholding exceeds 5 percent after repurchase	FW
Dec. 16	Carasent AB (OM:CARA) announces an Equity Buyback for 10% of its issued share capital.	CI